News & Comment
-
-
Comment |
Time to revisit the use of G-CSF after allogeneic haematopoietic cell transplantation in COVID-19 era?
- Alexandre E. Malek
-
Correspondence |
Comment on “Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy”
- Haitang Yang
- , Sean R. R. Hall
- , Beibei Sun
- & Feng Yao
-
Editorial |
The role of Schlafen 11 (SLFN11) as a predictive biomarker for targeting the DNA damage response
- Niamh Coleman
- , Bingnan Zhang
- , Lauren A. Byers
- & Timothy A. Yap
-
Correspondence |
Response to Comment on “Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy”
- Michael G. White
- & Oliver S. Eng
-
Correspondence |
Comment on “Identification of EMT-related high-risk stage II colorectal cancer and characterisation of metastasis-related genes”
- Maurice B. Loughrey
- , Natalie C. Fisher
- , Aoife J. McCooey
- & Philip D. Dunne
-
Editorial
| Open AccessSummary of ‘The current status and future perspectives on the management of stage III NSCLC: a focus on unresectable cancer treatment paradigms’
- Luis Paz-Ares
-
Editorial
| Open AccessForeword to ‘The current status and future perspectives on the management of stage III NSCLC: a focus on unresectable cancer treatment paradigms’
- Luis Paz-Ares
-
Comment
| Open AccessCOVID-19 vaccine race: watch your step for cancer patients
- Raphaelle Fanciullino
- , Joseph Ciccolini
- & Gerard Milano
-
Editorial |
Correlation of anti-tumour drug resistance with epigenetic regulation
- Takuma Hayashi
- & Ikuo Konishi
-
Comment |
Phosphatase, pseudo-phosphatase, or both? Understanding PRL oncogenicity
- Kalle Gehring
- & Hiroaki Miki
-
Editorial |
Putting Warburg to work: how imaging of tumour acidosis could help predict metastatic potential in breast cancer
- Michala Gylling Rolver
- & Stine Falsig Pedersen
-
-
Comment
| Open AccessPractical early cancer detection: distinguishing stable from unstable genomes in pre-cancerous tissues
- Sarah Killcoyne
- & Rebecca C. Fitzgerald
-
Correspondence |
Comment on “Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position”
- Ali Arshad
- , Ashley Dennison
- , Mark A. Taylor
- , Andrew Cook
- & John N. Primrose
-
Correspondence |
Reply to Comment on “The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic”
- Christopher M. Jones
- , Ganesh Radhakrishna
- , Katharine Aitken
- , John Bridgewater
- , Pippa Corrie
- , Martin Eatock
- , Rebecca Goody
- , Paula Ghaneh
- , James Good
- , Derek Grose
- , Daniel Holyoake
- , Arabella Hunt
- , Nigel B. Jamieson
- , Daniel H. Palmer
- , Zahir Soonawalla
- , Juan W. Valle
- , Maria A. Hawkins
- & Somnath Mukherjee
-
Correspondence
| Open AccessComment on: “Tumour-agnostic drugs in paediatric cancers”, Chisholm et al., BJC 2020
- Thomas Richard William Oliver
- , Thomas John Jackson
- , Olumide Ogunbiyi
- , Neil Sebire
- , Olga Slater
- , Mette Jorgensen
- & Sam Behjati
-
Correspondence |
Reply to ‘Comment on “Tumour-agnostic drugs in paediatric cancers”’
- Julia C. Chisholm
- , Fernando Carceller
- & Lynley V. Marshall
-
Editorial |
Quality improvement for cancer multidisciplinary teams: lessons learned from the Anglian Germ Cell Cancer Collaborative Group
- Tayana Soukup
- , Nick Sevdalis
- , James S. A. Green
- & Benjamin W. Lamb
-
Editorial |
Bromodomain inhibitors a decade later: a promise unfulfilled?
- Monica M. Mita
- & Alain C. Mita
-
Editorial |
Combining precision medicine and prophylaxis in oesophageal squamous cell carcinoma
- Mark A. Baxter
- , Lindsay C. Spender
- & Russell D. Petty
-
Correspondence |
Comment on: the myth of pulmonary metastasectomy
- Matthieu Zellweger
- & Michel Gonzalez
-
Correspondence |
Reply to ‘Comment on “The myth of pulmonary metastasectomy’”
- Fergus Macbeth
- & Dame Lesley Fallowfield
-
Comment |
Standards of care in mesothelioma treatment
- Susan V. Harden
- , Liz Darlison
- , Paul Beckett
- & Anna C. Bibby
-
Editorial |
Bowel inflammation in cancer patients: the microbiome, antibiotics and interleukin-9
- Niels Halama
-
Comment |
Is ovarian cancer surgery stuck in the dark ages?: a commentary piece reviewing surgical technologies
- David L. Phelps
- , Srdjan Saso
- & Sadaf Ghaem-Maghami
-
Comment |
T-cell tumour exclusion and immunotherapy resistance: a role for CAF targeting
- Christopher J. Hanley
- & Gareth J. Thomas
-
Comment |
Let the question determine the methods: descriptive epidemiology done right
- Sara Conroy
- & Eleanor J. Murray
-
Editorial |
Miliary breast cancer brain metastasis: a rare and aggressive form of central nervous system metastasis
- Matthew N. Mills
- & Kamran A. Ahmed
-
Correspondence |
Response to the comment on “Development of PancRISK, a urine biomarker-based risk score for stratified screening of pancreatic cancer patients”
- Oleg Blyuss
- & Tatjana Crnogorac-Jurcevic
-
Correspondence |
Comment on: ‘Development of PancRISK, a urine biomarker-based risk score for stratified screening of pancreatic cancer patients’
- Margot De Marco
- , Alessandra Rosati
- , Maria Caterina Turco
- & Liberato Marzullo
-
Correspondence |
Comment on: Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis
- Pei Pei Che
- , Alessandro Gregori
- , Godefridus J. Peters
- , Max Dahele
- , Peter Sminia
- & Elisa Giovannetti
-
Correspondence |
Reply letter to comments on: Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis
- Zhihong Xu
- , Srinivasa Pothula
- , David Goldstein
- , Romano C. Pirola
- , Jeremy S. Wilson
- & Minoti V. Apte
-
Correspondence |
Comment on: “UGT2B17 modifies drug response in chronic lymphocytic leukaemia”
- Spyros I. Papamichos
- & Christof Jungbauer
-
Correspondence |
Reply to Comment on “UGT2B17 modifies drug response in chronic lymphocytic leukaemia”
- Chantal Guillemette
- , Michèle Rouleau
- , Katrina Vanura
- & Éric Lévesque
-
Comment |
Reflections on the upsurge of virtual cancer conferences during the COVID-19 pandemic
- Valerie Speirs
-
Comment |
Increasing operational and scientific efficiency in clinical trials
- Deirdre Kelly
- , Anna Spreafico
- & Lillian L. Siu
-
Correspondence |
Comment on “Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort”
- Abhijeet Singh
- , Anand Subash
- & Piyush Sinha
-
Correspondence |
Reply to Comment(s) on “Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort”
- Iain Hutchison
- & Allan Hackshaw
-
Correspondence |
Comment on “Nationwide randomised trial evaluating elective neck dissection for early-stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort.”
- Harsh Dhar
- , Richa Vaish
- & Anil K. D’Cruz
-
-
Comment |
Polygenic risk score opportunities for early detection and prevention strategies in endometrial cancer
- Tracy A. O’Mara
- & Emma J. Crosbie
-
Comment |
Vitamin D supplementation: a potential therapeutic agent for metastatic colorectal cancer
- Chen Yuan
- & Kimmie Ng
-
Announcement |
Referee acknowledgement for 2019
-
-
-
Comment |
Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy
- Kamal S. Saini
- , Carlo Lanza
- , Marco Romano
- , Evandro de Azambuja
- , Javier Cortes
- , Begoña de las Heras
- , Javier de Castro
- , Monika Lamba Saini
- , Sibylle Loibl
- , Giuseppe Curigliano
- , Chris Twelves
- , Manuela Leone
- & Mrinal M. Patnaik
-
Comment |
Concurrent chemo-radiotherapy with proton therapy: reduced toxicity with comparable oncological outcomes vs photon chemo-radiotherapy
- Brian C. Baumann
- , Dennis E. Hallahan
- , Jeff M. Michalski
- , Carlos A. Perez
- & James M. Metz
-
-
Comment |
Immune checkpoint blockade: releasing the breaks or a protective barrier to COVID-19 severe acute respiratory syndrome?
- Oliver J. Pickles
- , Lennard Y. W. Lee
- , Thomas Starkey
- , Luke Freeman-Mills
- , Anna Olsson-Brown
- , Vinton Cheng
- , Daniel J. Hughes
- , Alvin Lee
- , Karin Purshouse
- & Gary Middleton
